CMV-MVA Triplex Vaccination of Stem Cell Donors to Enhance CMV Specific Immunity and Prevent CMV Viremia in Recipients After Stem Cell Transplant
Phase of Trial: Phase II
Latest Information Update: 03 Dec 2018
At a glance
- Drugs MVA CMV (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Therapeutic Use
- 11 Jul 2018 Planned End Date changed from 18 Aug 2019 to 18 Oct 2019.
- 11 Jul 2018 Planned primary completion date changed from 18 Aug 2019 to 18 Oct 2019.
- 11 Jul 2018 Status changed from not yet recruiting to recruiting.